After adjusting for age, tumor location, T stage, number of positive nodes, number of nodes dissected, histological grade, LVI and ER-, PR- and HER2-status, the multivariate analysis showed PMRT significantly reduced LRR (hazard ratio [HR] = 0.30, 95% CI: 0.17–0.53, p <  0.001), and increased DFS (HR = 0.71, 95% CI: 0.53–0.96, p = 0.028), but had no significant influence on DM (HR = 0.83, 95% CI: 0.59–1.15, p = 0.258), or OS (HR = 0.64, 95% CI: 0.40–1.03, p = 0.066), compared with no PMRT. This evidence concerns the gene ERBB2 and neoplasm.